TScan Therapeutics, Inc. - Laporan Laba Rugi (TTM)

TScan Therapeutics, Inc.
US ˙ NasdaqGM ˙ US89854M1018

Laporan Laba Rugi (TTM)

Laporan Laba Rugi TScan Therapeutics, Inc. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 1 3 6 8 10 11 12 13 14 17 16 17 21 15 12 9 3 4 7
Change (%) 186.82 91.52 35.60 25.48 9.80 10.85 7.70 1.81 27.94 -5.24 3.19 24.31 -29.63 -17.63 -23.26 -69.92 57.00 57.45
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 21 24 30 38 45 52 56 57 60 67 74 81 3 6 12 100 5 10 16
Change (%) 14.78 26.67 28.05 17.34 16.35 7.06 1.47 5.27 11.85 10.06 10.47 -96.46 107.02 94.89 765.24 -95.17 101.75 58.88
% of Revenue 1,896.50 758.93 501.96 474.02 443.29 469.74 453.68 427.43 441.96 386.37 448.78 480.43 13.66 40.20 95.11 1,072.44 172.09 221.15 223.16
Gross Operating Profit -19 -21 -24 -30 -35 -41 -44 -44 -46 -50 -57 -64 18 9 1 -91 -2 -5 -9
Change (%) 5.20 16.83 26.18 15.17 18.26 6.04 -0.29 6.33 7.15 15.41 12.56 -128.21 -51.26 -93.27 -15,375.17 -97.77 163.84 60.06
% of Revenue -1,796.50 -658.93 -401.96 -374.02 -343.29 -369.74 -353.68 -327.43 -341.96 -286.37 -348.78 -380.43 86.34 59.80 4.89 -972.44 -72.09 -121.15 -123.16
SG&A 7 8 10 12 14 16 18 19 20 24 25 26 26 26 27 28 30 32 33
Change (%) 18.81 20.13 24.95 15.03 13.65 13.25 4.84 9.07 16.08 7.29 3.88 0.08 -2.60 4.84 5.63 6.55 5.12 4.15
% of Revenue 621.29 257.36 161.43 148.74 136.36 141.14 144.20 140.36 150.37 136.43 154.48 155.51 125.20 173.30 220.58 303.63 1,075.53 720.15 476.37
R&D 85 85 85 103 103 103
Change (%) 0.00 0.00 0.00 0.00
% of Revenue 405.14 575.73 698.99 3,640.06 2,318.57 1,472.55
OpEx 27 32 40 50 59 68 74 75 80 91 99 108 115 117 124 129 138 144 151
Change (%) 15.77 25.01 27.30 16.79 15.72 8.49 2.29 6.21 12.92 9.34 8.78 6.34 2.09 5.90 4.07 6.84 4.71 4.91
% of Revenue 2,517.79 1,016.29 663.39 622.75 579.65 610.88 597.88 567.80 592.32 522.80 603.26 635.94 544.00 789.22 1,014.69 1,376.07 4,887.68 3,259.87 2,172.07
Operating Income -26 -29 -34 -42 -49 -57 -61 -62 -67 -73 -83 -91 -93 -102 -112 -119 -135 -140 -144
Change (%) 8.70 17.76 25.82 15.13 16.95 8.03 1.20 7.15 9.87 12.79 9.89 2.98 9.23 9.31 7.06 12.85 3.62 3.25
% of Revenue -2,417.79 -916.29 -563.39 -522.75 -479.65 -510.88 -497.88 -467.80 -492.32 -422.80 -503.26 -535.94 -444.00 -689.22 -914.69 -1,276.07 -4,787.68 -3,159.87 -2,072.07
Interest Expense -0 -1 -2 -3 -4 -4 -4 -4 -4 -4 -3 -3
Change (%) 485.07 81.29 45.45 25.19 -3.17 0.08 -0.45 -0.64 -1.83 -7.66 -7.80
% of Revenue -1.51 -8.69 -12.31 -18.90 -22.93 -17.86 -25.40 -30.70 -39.75 -129.72 -76.29 -44.68
Net Income -26 -29 -34 -42 -49 -57 -61 -62 -66 -73 -82 -88 -89 -97 -104 -111 -127 -131 -137
Change (%) 9.09 17.76 25.83 15.14 16.95 7.78 0.66 7.33 9.68 12.32 8.28 1.01 8.49 7.87 6.60 14.55 3.13 4.02
% of Revenue -2,408.02 -915.87 -563.14 -522.54 -479.49 -510.72 -496.57 -464.10 -489.26 -419.40 -497.14 -521.63 -423.86 -653.50 -855.84 -1,188.88 -4,527.66 -2,974.08 -1,964.88

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista